Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peter, R.
Right arrow Articles by Owens, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peter, R.
Right arrow Articles by Owens, D. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:560-565, 2005
© 2005 by the American Diabetes Association, Inc.

Clinical Care/Education/Nutrition
Original Article

Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes

Rajesh Peter, MRCP1, Stephen D. Luzio, PHD1, Gareth Dunseath, MPHIL1, Andy Miles, PHD2, Barry Hare, PHD2, Karianne Backx, PHD2, Vassen Pauvaday, MRCP1 and David R. Owens, MD1

1 Diabetes Research Unit, Llandough Hospital, Penarth, South Glamorgan, U.K
2 School of Sport, PE and Recreation, University of Wales Institute, Cardiff, South Glamorgan, U.K

Address correspondence and reprint requests to Prof. D.R. Owens, Diabetes Research Unit, First Floor, Academic Centre, Llandough Hospital, Penlan Road, Penarth, South Glamorgan CF64 2XX, Wales, U.K. E-mail: owensdr{at}cf.ac.uk

OBJECTIVE—To study the effects of exercise on the absorption of the basal long-acting insulin analog insulin glargine (Lantus), administered subcutaneously in individuals with type 1 diabetes.

RESEARCH DESIGN AND METHODS—A total of 13 patients (12 men, 1 woman) with type 1 diabetes on a basal-bolus insulin regimen were studied. 125I-labeled insulin glargine at the usual basal insulin dose was injected subcutaneously into the thigh on the evening (2100) before the study day on two occasions 1 week apart. Patients were randomly assigned to 30 min intense exercise (65% peak oxygen uptake [VO2peak]) on one of these visits. The decay of radioactive insulin glargine was compared on the two occasions using a thallium-activated Nal gamma counter. Blood samples were collected at regular intervals on the study days to assess plasma glucose and insulin profiles.

RESULTS—No significant difference was found in the 125I-labeled insulin glargine decay rate on the two occasions (exercise vs. no exercise; repeated-measures ANOVA, P = 0.548). As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [{Delta}AUC] glucose: –0.39 ± 0.11 vs. –1.30 ± 0.16 mmol · l–1 · h–1; nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions ({Delta}AUC insulin: –2.1 ± 3.9 vs. 1.5 ± 6.2 pmol · l–1 · h–1; nonexercise versus exercise; P = 0.507).

CONCLUSIONS—An intense 30-min period of exercise does not increase the absorption rate of the subcutaneously injected basal long-acting insulin analog insulin glargine in patients with type 1 diabetes.

Abbreviations: {Delta}AUC, area under the curve above fasting


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

Exercise and Type 1 Diabetes




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.